Chloramphenicol

CHEMBL130 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
323.1 g/mol
LogP
1.1
Phase
4

A broad-spectrum antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, active against a wide range of gram-positive, gram-negative, and anaerobic bacteria. Its systemic use is restricted due to the risk of serious blood disorders, including aplastic anemia. Topical ophthalmic formulations remain widely used for eye infections.

น้ำหนักโมเลกุล

323.1300 g/mol

LogP

1.10

TPSA

115.00 Ų

Lipinski RO5

ผ่าน

กลไกการออกฤทธิ์

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C(N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl

InChI

InChI=1S/C11H12Cl2N2O5/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20/h1-4,8-10,16-17H,5H2,(H,14,18)/t8-,9-/m1/s1

Molecular Formula

C11H12Cl2N2O5

HBD / HBA

3 / 5

พันธะที่หมุนได้

5

อะตอมหนัก

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

A broad-spectrum antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, active against a wide range of gram-positive, gram-negative, and anaerobic bacteria. Its systemic use is restricted due to the risk of serious blood disorders, including aplastic anemia. Topical ophthalmic formulations remain widely used for eye infections.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Chloramphenicol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL130. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5959. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.